Effect of Trimetazidine Dihydrochloride Tablets adjuvant therapy on inflammatory reaction, oxidative stress, vascular endothelial function and myocardial function in patients with coronary heart disease complicated with heart failure

摘要

Objective: To investigate the effects of Trimetazidine Dihydrochloride Tablets on inflammatoryreaction, oxidative stress, vascular endothelial function and myocardial function in patientswith coronary heart disease complicated with heart failure. Methods: A total of 98 patientswith coronary heart disease and heart failure who met the criteria of the study were selectedas the subjects, based on the random data table they were divided into the control group(n=49) and observation group (n=49), the patients in the control group were treated withMetoprolol Tartrate Sustained-release Tablets treatment, and the patients in the observationgroup were treated with Metoprolol Tartrate Sustained-release Tablets combined withTrimetazidine Dihydrochloride Tablets, the levels of inflammatory reaction, oxidative stress,vascular endothelial function and myocardial function indexes were compared between thetwo groups before and after treatment. Results: The difference of the CRP, TNF-α, MDA,SOD, NO, ET-1, LVEF, LVEDD and LVESD levels in the two groups before treatment werenot statistically significant; Compared with the levels of the two groups before treatment, thetwo groups of CRP, TNF-α, MDA, ET-1, LVEDD and LVESD levels after treatment weresignificantly decreased, and the level of the observation group after treatment was significantlylower than those levels in the control group, the difference was statistically significant; Thelevels of SOD, NO and LVEF of the two groups after treatment were significantly higher thanthose in the same group before treatment, and the observation group levels [(88.09±7.51) U/ml, (72.58±14.64) mol/L, (48.34±5.09)% ] were significantly higher than the control group[(79.44±7.27) U/ml, (61.89±11.06) mol/L, (44.19±4.58)%], the difference was statisticallysignificant. Conclusion: Trimetazidine Dihydrochloride Tablets in the treatment of coronaryheart disease with heart failure can effectively inhibit the release of inflammatory factors,improve oxidative stress state, vascular endothelial function and myocardial function, has animportant clinical value.